USE OF PRIDOPIDINE AND ANALOGS FOR THE TREATMENT OF ANXIETY AND DEPRESSION
The invention provides a method of reducing anxiety and/or depression in a subject comprising administering to the subject a pharmaceutical composition comprising pridopidine or pharmaceutical acceptable salts and at least one of compounds 1-8 or pharmaceutical acceptable salt thereof described herein, effective to reduce anxiety and/or depression in a subject.
1 . A method of reducing anxiety, depression or combination thereof in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof and at least one of compounds 1-8:
or pharmaceutically acceptable salt thereof effective to reduce anxiety, depression or combination thereof in the subject.
2 . The method of claim 1 , wherein anxiety is measured by the State-Trait Anxiety Inventory (STAI), the Fear Survey Schedule, Beck Anxiety Inventory (BAI), Brief Fear of Negative Evaluation Scale—BFNE, Clinician Administered PTSD Scale (CAPS), Daily Assessment of Symptoms—Anxiety, Generalized Anxiety Disorder 7 (GAD-7), Hamilton Anxiety Scale (HAM-A), Hospital Anxiety and Depression Scale (HADS-A), Leibowitz Social Anxiety Scale (LSAS), Overall Anxiety Severity and Impairment Scale (OASIS), Panic and Agoraphobia Scale (PAS), Panic Disorder Severity Scale (PDSS), PTSD Symptom Scale—Self-Report Version, Social Phobia Inventory (SPIN), Trauma Screening Questionnaire, Yale-Brown Obsessive Compulsive Scale (Y-BOCS), PBA-S, marble burying, ultrasonic vocalizations or the Zung Self-Rating Anxiety Scale.
3 . The method of claim 2 , wherein anxiety is reduced by at least one increment.
4 . The method of claim 1 , wherein depression is measured by Hamilton Rating Scale for Depression (HAM-D), Beck Depression Inventory (BDI), Beck Hopelessness Scale, Centre for Epidemiological Studies-Depression Scale (CES-D), Patient Health Questionnaire, Center for Epidemiological Studies Depression Scale for Children (CES-DC), Clinically Useful Depression Outcome Scale, Diagnostic Inventory for Depression, Edinburgh Postnatal Depression Scale (EPDS), Inventory of Depressive Symptomatology, Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale, Kutcher Adolescent Depression Scale (KADS), Major Depression Inventory (MDI), Montgomery-Asberg Depression Rating Scale (MADRS), Mood and Feelings Questionnaire (MFQ), Zung Self-Rating Depression Scale, forced swim test, or Cornell Scale for Depression in Dementia (CSDD).
5 . The method of claim 4 , wherein depression is reduced by at least one increment.
6 . (canceled)
7 . The method of claim 1 , wherein the anxiety disorder is generalized anxiety disorder (GAD), panic disorder, a phobic disorder, social phobia, agoraphobia, or trauma- and stressor-related disorders.
8 . The method of claim 7 , wherein the trauma- and stressor-related disorder is acute stress disorder (ASD), or posttraumatic stress disorder (PTSD).
9 . (canceled)
10 . The method of claim 1 , wherein the depressive disorder is major depressive disorder, persistent depressive disorder, premenstrual dysphoric disorder, other depressive disorder, depressive disorder due to another medical condition, substance/medication-induced depressive disorder, perinatal depression, peripartum-onset depression, seasonal affective disorder, or psychotic depression.
11 . The method of claim 1 , wherein the subject is afflicted with a neurodegenerative disease.
12 . The method of claim 1 , wherein the subject is afflicted with Huntington disease.
13 . The method of claim 12 , wherein the subject is afflicted with early stage Huntington disease.
14 . The method of claim 12 , wherein the subject is afflicted with Stage 1 or Stage 2 Huntington disease.
15 . The method of claim 14 the subject has greater than or equal to 36 CAG repeats in the huntingtin gene.
16 . The method of claim 15 , wherein the subject has greater than 44 CAG repeats in the huntingtin gene.
17 . The method of claim 14 , wherein the subject is presymptomatic or symptomatic.
18 . (canceled)
19 . The method of claim 14 , wherein the method comprises reducing anxiety in a subject afflicted with early stage Huntington disease.
20 . The method of claim 14 , wherein the method comprises reducing depression in a subject afflicted with any one of the following: Stage 1 Huntington disease, Stage 2 Huntington disease, Stage 3 Huntington disease, Stage 4 Huntington disease and Stage 5 Huntington disease.
21 . (canceled)
22 . The method of claim 1 , wherein the subject is experiencing at least one symptom of anxiety, wherein the at least one symptom comprises restlessness, heart palpitations, hyperventilation, heavy sweating, muscle twitching, weakness, lethargy, insomnia, nausea, repetitive behavior, or any combination thereof.
23 . (canceled)
24 . The method of claim 1 , wherein the subject is experiencing at least one symptom of depression, and wherein the at least one symptom of depression comprises depressed mood, anhedonia, low energy levels, feelings of guilt, psychomotor retardation, agitation, suicidal ideations poor concentration and indecisiveness, or any combination thereof.
25 . The method of claim 1 , wherein the composition comprises pridopidine or a pharmaceutically acceptable salt thereof and at least one of compound 1, compound 4, pharmaceutically acceptable salt thereof or combination thereof.
26 . The method of claim 1 , wherein the composition comprises pridopidine or a pharmaceutically acceptable salt thereof and compound 1 or pharmaceutically acceptable salt thereof.
27 . The method of claim 1 , wherein the composition comprises pridopidine or a pharmaceutically acceptable salt thereof, compound 1 and compound 4 or pharmaceutically acceptable salt thereof.
28 . The method of claim 1 , wherein the composition comprises pridopidine salt, wherein the salt is hydrochloride, hydrobromide, nitrate, perchlorate, phosphate, sulphate, formate, acetate, aconate, ascorbate, benzenesulphonate, benzoate, cinnamate, citrate, embonate, enantate, fumarate, glutamate, glycolate, lactate, maleate, malonate, mandelate, methane-sulphonate, naphthalene-2-sulphonate, phthalate, salicylate, sorbate, stearate, succinate, tartrate or toluene-p-sulphonate salt.
29 . The method of any one of claim 1 , wherein the composition is an oral dosage unit comprising between 0.5-315 mg pridopidine.
30 - 35 . (canceled)
36 . The method of claim 1 , wherein the weight ratio between the pridopidine and at least one of compounds 1-8 is in the range of 1:0.001 to 1:0.1.
37 . The method of claim 36 , wherein the weight ratio between the pridopidine and at least one of compounds 1-8 is in the range of 1:0.005 to 1:0.1.
38 . The method of claim 36 , wherein the weight ratio between the pridopidine and at least one of compounds 1-8 is in the range of 1:0.001 to 1:0.005.
39 . The method of claim 29 , wherein the oral dosage unit is formulated as a tablet, a capsule, a pill, powder, liquid solution or as a liquid suspension.
40 . The method of claim 1 , wherein the pharmaceutical composition is administered once daily, or more than once daily.
41 . (canceled)